Holen Sie sich die Stockscreener-App
2.28
1.94%
-0.045
Schlusskurs vom Vortag:
$2.325
Offen:
$2.35
24-Stunden-Volumen:
36,195
Relative Volume:
0.09
Marktkapitalisierung:
$18.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-0.407
EPS:
-5.6013
Netto-Cashflow:
$-7.45M
1W Leistung:
-2.15%
1M Leistung:
+4.59%
6M Leistung:
-85.90%
1J Leistung:
-84.28%
1-Tages-Spanne:
$2.25
$2.36
1-Wochen-Bereich:
$2.14
$2.38
52-Wochen-Spanne:
$1.80
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Vergleichen Sie CRVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.28 | 18.82M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-12-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-18 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-07-26 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CervoMed (NASDAQ:CRVO) Raised to Buy at D. Boral Capital - Armenian Reporter
Why CervoMed (CRVO) Is Advancing Today - Yahoo Canada Finance
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Boral Capital raises CervoMed stock to Buy, sets $10 target By Investing.com - Investing.com South Africa
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Boral Capital raises CervoMed stock to Buy, sets $10 target - Investing.com
How Are Things Looking For CervoMed Inc (NASDAQ: CRVO) For The Short Term? - Stocks Register
CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average PT from Brokerages - Defense World
Perigon Wealth Management LLC Makes New Investment in CervoMed Inc. (NASDAQ:CRVO) - Defense World
CervoMed Provides Update on Neflamapimod DLB Program as - GlobeNewswire
CervoMed reports progress in dementia drug trial - MSN
CervoMed Updates on Neflamapimod Trials for Dementia - TipRanks
CervoMed reports progress in dementia drug trial By Investing.com - Investing.com UK
Clinical Trial Setback: CervoMed's Dementia Drug Gets Second Chance with Enhanced Formula - StockTitan
CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewswire
Major Breakthrough in Lewy Body Dementia Treatment: CervoMed Reveals Game-Changing Clinical Data - StockTitan
CervoMed Inc. (NASDAQ:CRVO) Stock Holdings Lifted by Barclays PLC - Defense World
Roth MKM Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average Price Target from Analysts - Defense World
AWM Investment Company, Inc. Reduces Stake in CervoMed Inc - GuruFocus.com
CervoMed (STU:DP8) Momentum Rank : 8 (As of Jan. 11, 2025) - GuruFocus.com
Geode Capital Management LLC Raises Holdings in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Barclays PLC Acquires 5,919 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
Brookline Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
State Street Corp Boosts Stake in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $42.00 - Defense World
HC Wainwright Brokers Reduce Earnings Estimates for CervoMed - Defense World
Enhanced Cognition: Lewy body dementia phase II pumps stock - BioWorld Online
HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN
Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World
CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World
CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan
CervoMed's dementia drug fails mid-stage trial, shares slump - MSN
Chardan Capital Downgrades CervoMed (CRVO) - MSN
What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance
Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK
CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada
CervoMed shares rating downgraded after trial data disappoints - Investing.com
Jones Trading Downgrades CervoMed (CRVO) - MSN
CervoMed's dementia drug fails to meet mid-stage trial goals - MSN
CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com
CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch
CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD
Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):